Dental pain management in medically compromised patients: A comprehensive review and proposal of an analgesic ladder

Abstract

Background:

Managing dental pain in medically compromised patients poses clinical challenges due to altered drug metabolism, systemic contraindications, and increased risk of adverse effects. Existing guidelines often lack specificity for this group, highlighting the need for a tailored approach to analgesic prescribing. This review aimed to survey the literature and propose an evidence-informed analgesic ladder for dental care in medically vulnerable patients.

Methods:

A comprehensive review was conducted using structured searches of PubMed, Scopus, Web of Science, and the Cochrane Library for studies published from January 2000 to May 2025. Eligible studies included randomized controlled trials (RCTs), systematic and narrative reviews, and clinical guidelines addressing dental analgesia in patients with conditions such as cardiovascular disease, renal or hepatic impairment, asthma, diabetes, and cancer. Forty-nine studies met the inclusion criteria. Findings were thematically analyzed by pain severity and patient-specific risk factors, forming the basis of a five-step analgesic ladder.

Results:

The proposed ladder offers a structured framework to guide dental clinicians in selecting analgesics based on pain intensity and patient medical conditions. It incorporates stepwise recommendations accounting for common comorbidities and contraindications, with emphasis on dose adjustment, combination therapy, and selective use of adjunctive analgesics.

Conclusion:

This review presents a practical, patient-centered analgesic ladder to support safer dental pain management in medically compromised individuals. Despite the limited availability of RCTs, this framework offers an evidence-informed tool for personalized dental pain care. Further research is needed to validate the model and explore the role of adjunctive analgesia.

Introduction

Pain control is a critical component of dental care, as it significantly influences patient comfort, treatment success, and adherence to postoperative instructions.[1] Dental procedures—such as tooth extractions, root canal treatments, and periodontal surgeries—are common sources of acute pain, requiring timely and appropriate pharmacologic intervention.[2,3] When pain is not adequately managed, patients may experience delayed recovery, increased psychological distress, and poor follow-up compliance.[4]

Among the commonly used analgesics in dentistry, non-opioid agents—especially paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs)—are widely favored due to their proven effectiveness and generally acceptable safety profiles in healthy individuals.[5,6] Paracetamol provides central analgesia and is well-tolerated in patients with gastrointestinal sensitivity or mild liver impairment.[7] NSAIDs, including ibuprofen and diclofenac, are especially valuable for their anti-inflammatory and analgesic actions. However, their use in patients with cardiovascular disorders, kidney dysfunction, or gastrointestinal conditions must be approached with caution. This is because prostaglandins, synthesized through the cyclooxygenase (COX) pathway, are essential for regulating renal blood flow, protecting gastric mucosa, and maintaining vascular balance.[8,9] Inhibiting COX—particularly COX-1—can interfere with these physiological processes and may worsen systemic health conditions in at-risk individuals.[10]

Concerns about opioid dependency, tolerance, and respiratory complications have prompted a shift towards multimodal analgesic protocols. The coadministration of NSAIDs and paracetamol has gained recognition as a powerful, opioid-sparing approach for managing dental pain.[11] In addition, incorporating corticosteroids, muscle relaxants, sedatives, and topical analgesics has broadened treatment strategies for conditions such as postsurgical swelling, trismus, and temporomandibular joint (TMJ) dysfunction.[12,13]

The World Health Organization’s (WHO) analgesic ladder—originally proposed for cancer pain—has been adapted to guide dental pain management. This stepwise model assists clinicians in selecting appropriate medications based on pain severity, patient comorbidities, and drug safety considerations.[3,14] As dentistry moves toward a more individualized approach, practitioners must remain informed about pharmacologic updates and best practices, especially for medically complex patients.[4,15]

In clinical practice, some dental practitioners may prescribe the same analgesic across all patient populations, either due to habit or concern over adverse reactions, while others may adopt new medications without fully understanding their pharmacologic profiles. Both scenarios risk either under-treatment or adverse outcomes. Therefore, a structured framework, such as a tiered analgesic ladder, can guide evidence-based decisions to select analgesics tailored to the patient’s condition and pain intensity.[5,7,14] This manuscript aims to survey the current literature on analgesic management for dental pain in medically compromised patients and to propose evidence-informed clinical practice guidelines, including a tailored analgesic ladder, to support safe and effective prescribing in dental practice for this population.

Methods

This article presents a comprehensive review designed to update and refine analgesic prescribing practices for dental treatment in medically compromised patients. A systematic review methodology was not adopted due to the scarcity of high-quality randomized controlled trials (RCTs) and the considerable heterogeneity in study designs, patient populations, and outcome measures in the available literature. Instead, this review integrates diverse forms of evidence to support a pragmatic, clinically oriented approach to dental pain management.

A structured, non-systematic literature search was conducted across four major databases: PubMed, Scopus, Web of Science, and the Cochrane Library. The search included studies published between January 2000 and May 2025. Keywords and Medical Subject Headings (MeSH) used included combinations of: “dental pain,” “oral surgery analgesia,” “NSAIDs,” “opioids,” “analgesic ladder,” “medically compromised patients,” “renal disease,” “hepatic impairment,” “cardiac conditions,” and “safe prescribing in dentistry.”

Inclusion criteria comprised studies evaluating the efficacy, safety, or clinical application of analgesics in dental treatment—particularly in patients with systemic comorbidities such as cardiovascular disease, diabetes, renal impairment, hepatic dysfunction, asthma, and cancer. Study types included were RCTs, systematic reviews, narrative reviews, clinical guidelines, case series, and observational studies. Studies were excluded if they involved non-human subjects, in vitro-only data, or lacked clear relevance to dental clinical practice.

The initial search yielded 612 articles. After removing duplicates, 417 titles and abstracts were screened for relevance. From these, 86 full-text articles were assessed, and 49 studies were ultimately included in the final synthesis. These consisted of 8 RCTs, 8 systematic reviews, 29 narrative or scoping reviews, and 4 clinical practice guidelines or expert consensus protocols. These studies evaluated a range of analgesics used in dental settings, focusing on their effectiveness, onset of action, duration of effect, safety profile, and contraindications across diverse patient populations.

Rather than applying a statistical meta-analysis, a thematic synthesis was employed to organize data into core clinical domains: analgesic classification, condition-specific preferred and contraindicated analgesics, efficacy of drug combinations, and the use of adjunctive therapies. Based on this synthesis, a practical five-step analgesic ladder was developed, aligning pain severity with safe pharmacologic options tailored to each patient’s medical risk profile.

This methodology emphasizes clinical relevance over statistical synthesis and aims to bridge the gap between pharmacologic evidence and real-world decision-making. It supports a rational, tiered approach to dental pain management that considers both the intensity of pain and the complexity of the patient’s medical condition.

Results

This comprehensive review aimed to construct a clinically relevant, stepwise analgesic ladder for dental pain management in medically compromised patients. Rather than relying on statistical synthesis, the findings were thematically organized to link pain intensity with suitable pharmacologic interventions, while accounting for comorbidities and drug-related contraindications. The final framework, informed by 49 selected publications, provides clinicians with structured guidance for individualized, safe, and effective pain control in complex dental cases.

A pooled analysis of 16 high-quality RCTs, systematic reviews, 29 narrative/scoping review articles, and 4 clinical practice guidelines led to the development of Tables 1-4. These tables represent the evidence-based classification of analgesics used in dentistry, optimal analgesic choices for medically compromised dental patients, the proposed analgesic ladder for dental pain, and the role of adjunctive analgesia.

Table 1.

Classification of analgesics in dentistry

Category	Scientific Name	Brand Example	Use in Dentistry	Common Side Effects	References
Non-acidic Analgesics	Paracetamol	Panadol®, Tylenol®	First-line, mild pain, safe in comorbidities	Liver toxicity (in overdose), rash	[1,5,15,16]
Acidic Analgesics (NSAIDs)	Ibuprofen, Diclofenac, Naproxen, Aspirin	Brufen®, Voltaren®, Naprosyn®, Disprin®	Moderate pain associated with infection, post surgical extractions, and TMJ disorders	Gastric irritation, bleeding, renal issues	[1,5,8,9,15,16,17,18,19]
Selective COX-2 Inhibitors	Celecoxib, Etoricoxib	Celebrex®, Arcoxia®	Alternative for GI-risk patients	Increased cardiovascular risk, headache	[15,16]
Opioid Analgesics	Tramadol, Codeine, Morphine	Tramal®, Solpadeine®, MST®	Severe pain, limited use	Nausea, constipation, dependency	[9,15,18]
Neuropathic Pain Agents	Carbamazepine, Gabapentin, Amitriptyline	Tegretol®, Neurontin®	Severe trigeminal nerve pain (trigeminal neuralgia), TMJ dislocation	Drowsiness, dizziness, mood changes	[20,21,22]
Sedative Adjuvants	Diazepam, Clonazepam, Baclofen	Valium®, Rivotril®	Myofascial pain, TMJ dysfunction	Sedation, dependence, muscle weakness	[23,24,25]

NSAIDs=non-steroidal anti-inflammatory drugs, COX-2=cyclooxygenase enzyme, TMJ=temporomandibular joint, GI=gastrointestinal, MST®: Morphine Sulfate Tablets

Table 4.

Adjunctive analgesia in dental pain management for medically compromised patients

Clinical Context	Adjunctive Analgesic	Contraindications/Precautions	Clinical Considerations
Postoperative pain, trismus, inflammatory conditions (e.g., Bell’s palsy)	Dexamethasone (8 mg IM/oral), Prednisone	Uncontrolled diabetes	Reduces inflammation and swelling; monitor glucose levels
Oral mucosal pain, ulcers, denture-related stomatitis	Lidocaine 2% gel, Benzydamine mouthwash, Orabase with triamcinolone	Allergy to components; overuse of topical steroids	Local relief with minimal systemic risk; preferred in systemic comorbidities
Pediatric teething pain	Paracetamol, Bonjela® (lidocaine + antiseptic)	Excess use of lidocaine in infants (toxicity risk)	Paracetamol is first-line; topical gels must be used with caution

IM=intramuscular

Table 1 categorizes the main types of analgesics used in dental practice, emphasizing their indications and clinical considerations. Paracetamol, marketed as Panadol® and Tylenol®, is a commonly preferred non-acidic analgesic due to its safety in patients with underlying health issues and is widely recommended for mild dental pain.[1,5,15,16] NSAIDs such as ibuprofen, diclofenac, naproxen, and aspirin—available as Brufen®, Voltaren®, Naprosyn®, and Disprin®—are typically used for managing moderate pain associated with infection, post surgical extractions, and TMJ disorders.[1,5,8,9,15,16,17,18,19]

Selective COX-2 inhibitors, including celecoxib and etoricoxib (e.g., Celebrex®, Arcoxia®), provide pain relief for patients who are at risk of gastrointestinal complications from traditional NSAIDs, though they may increase cardiovascular risk.[15,16] Opioids such as tramadol, codeine, and morphine—sold under names like Tramal®, Solpadeine®, and MST®—are reserved for severe pain and used with caution due to their potential for adverse effects, including dependency and gastrointestinal symptoms.[9,15,18]

For neuropathic pain conditions like trigeminal neuralgia, agents such as carbamazepine, gabapentin, and amitriptyline (e.g., Tegretol®, Neurontin®) are employed due to their efficacy in managing nerve-related pain and TMJ-related dislocation.[20,21,22] Sedative medications, including diazepam, clonazepam, and baclofen (Valium®, Rivotril®), help treat muscular and functional jaw disorders, such as TMJ dysfunction and myofascial pain.[23,24,25]

Each drug class has a distinct side effect profile. Paracetamol, while generally well-tolerated, may cause liver toxicity in overdose.[1] NSAIDs can lead to gastrointestinal upset, bleeding, and kidney dysfunction.[5,8,9,18] COX-2 inhibitors are gentler on the stomach but can pose cardiovascular risks.[15] Opioids may result in nausea, sedation, constipation, and dependence.[9] Neuropathic agents often cause drowsiness and mood alterations,[21,22] while sedatives may lead to muscle relaxation alongside sedation or dependence.[23]

The evaluation of analgesic use in medically compromised dental patients, as summarized in Table 2, highlights the need for condition-specific drug selection to ensure both safety and therapeutic efficacy. In patients with cardiovascular disease, including hypertension, paracetamol and selective COX-2 inhibitors are favored, while traditional NSAIDs are avoided due to their association with increased blood pressure and cardiovascular events. Although low-dose aspirin is commonly prescribed for secondary prevention, it is unsuitable as an analgesic in these cases because of its bleeding risk, particularly when blood pressure is not well controlled.[32,34] For patients with asthma, non-selective NSAIDs and aspirin pose a risk of bronchospasm, making paracetamol and COX-2 selective inhibitors the safer options.[32] Those with peptic ulcer disease benefit from paracetamol and topical analgesics, while NSAIDs and aspirin are contraindicated due to gastrointestinal complications.[31] In renal disease, cautious use of dose-adjusted paracetamol is recommended, avoiding NSAIDs and COX-2 inhibitors because of nephrotoxicity risks.[35] Patients with liver impairment should avoid high doses of paracetamol and opioids, with short-term ibuprofen being a potential alternative.[6] For diabetics, NSAIDs can be used with close monitoring of glycemic levels, whereas corticosteroids are discouraged in uncontrolled diabetes due to their metabolic impact.[29] In oncology settings, particularly for patients undergoing palliative care, opioids like morphine are effective for pain control, but NSAIDs must be used with caution when thrombocytopenia is present.[4,33] These recommendations are backed by evidence from RCTs, systematic reviews, and clinical guidelines.[3,5,7,8,9,17,18,26]

Table 2.

Optimal analgesics in medically compromised dental patients

Medical Condition	Preferred Analgesics	Contraindicated Analgesics	Evidence Level (References)
Cardiovascular Disease* + Hypertension	Paracetamol, COX-2 inhibitors (short-term)	NSAIDs (long-term), Ibuprofen (high dose), Aspirin (when used for analgesia)	Guideline,[3] Review,[2] RCT,[1,7,26] Review,[27] Review[28]
Diabetes	Paracetamol, NSAIDs (monitor glucose)	Corticosteroids (uncontrolled diabetes)	RCT,[1,7] Review,[29] Review[8]
Renal Disease	Paracetamol (dose-adjusted)	NSAIDs, COX-2 inhibitors	Review,[30] Guideline,[3] Review[28]
Liver Disease	Ibuprofen (short-term)	Paracetamol (high dose), opioids	Review,[6] RCT,[1] Review[28]
Pregnancy	Paracetamol (all trimesters), limited COX-2 (under specialist guidance)	NSAIDs (especially third trimester), opioids (long-term)	Guideline,[3] Review,[9] Review[2]
Peptic Ulcer	Paracetamol, topical agents	NSAIDs, aspirin	Guideline,[3] Review,[31] Review[28]
Asthma	Paracetamol, selective COX-2 inhibitors	Aspirin, non-selective NSAIDs	Guideline,[3] Review,[32] Review[2]
Bleeding Disorder	Paracetamol, COX-2 inhibitors	Aspirin, traditional NSAIDs	Guideline,[3] Review,[32] Review[28]
Elderly Patients	Paracetamol, short-term COX-2 inhibitors	Long-term NSAIDs, opioids (cautious use)	Guideline,[3] Review,[2] Review[5]
Cancer	Morphine (in palliative), paracetamol	NSAIDs (if thrombocytopenia)	Guideline,[3] Retrospective study,[4] RCT,[33] Review[13]

*Cardiovascular Disease: Aspirin is used for secondary prevention but should not be used for analgesia due to bleeding risk, especially in uncontrolled hypertension. COX-2=cyclooxygenase enzyme, NSAIDs=non-steroidal anti-inflammatory drugs, RCT=randomized controlled trials

Table 3 outlines a clinical analgesic ladder specifically designed for dental pain management in medically compromised patients, incorporating evidence from systematic reviews and RCTs. For mild pain, paracetamol remains the first-line agent due to its safety in hepatic and renal dysfunction when used judiciously.[1,6] In moderate pain, a combination of paracetamol with NSAIDs like ibuprofen or diclofenac is effective, but caution is required in patients with gastrointestinal, renal, or cardiovascular comorbidities.[2,28,36] Systematic reviews highlight the enhanced efficacy of NSAID-paracetamol combinations over monotherapy, particularly for postoperative dental pain.[5,37] For severe pain, tramadol or hospital-based morphine may be considered in short-term settings, with close monitoring in individuals with organ dysfunction or a history of substance use.[3,27,38] Neuropathic dental pain, although less common, is best managed using agents like gabapentin, carbamazepine, or amitriptyline, as supported by recent clinical guidelines and pharmacological evidence.[20,21] Myofascial pain management can include adjunctive muscle relaxants, yet these must be used cautiously in elderly patients and those with substance misuse risks due to sedation potential.[23,24] This stepwise framework provides a reliable tool to optimize pain control in dental patients with systemic conditions while minimizing the risk of adverse effects.

Table 3.

Analgesic ladder for dental pain in medically compromised patients

Step and Pain Severity	Recommended Analgesics	Contraindications	Notes/Special Considerations
Step 1 Mild Pain	Paracetamol (Acetaminophen)	Severe hepatic impairment	Safe in most patients; adjust dose and monitor LFTs in liver disease
Step 2 Moderate Pain	Paracetamol+Ibuprofen (or Diclofenac)	Peptic ulcer, renal disease, NSAID-sensitive asthma, uncontrolled hypertension	Use lowest effective NSAID dose; avoid in GI/renal risks; monitor BP
Step 3 Severe Pain	Tramadol±Paracetamol; Morphine (hospital-only)	Severe hepatic/renal dysfunction, opioid abuse history, respiratory depression	Short-term use only; monitor for sedation, respiratory function, dependency
Step 4 Neuropathic Pain	Carbamazepine±Gabapentin, Amitriptyline	Elderly (fall risk), cardiac arrhythmias, renal impairment	Start low, go slow; monitor mental status, ECG, and renal function
Step 5 Myofascial Pain	Paracetamol + NSAID±Muscle Relaxants (Diazepam, Clonazepam, Baclofen)	Elderly, hepatic dysfunction, substance use disorders	Short-term use only; monitor for sedation and dependency

NSAIDs=non-steroidal anti-inflammatory drugs, LFTs=liver function tests, GI=gastrointestinal, BP=blood pressure, ECG=electrocardiogram

In medically compromised dental patients, adjunctive analgesic strategies are essential to enhance pain relief while minimizing systemic risk. Table 4 summarizes the use of adjunctive analgesia in dental pain management for medically compromised patients. Corticosteroids such as dexamethasone (8 mg intramuscular (IM)/oral) and prednisone have demonstrated effectiveness in reducing postoperative inflammation, pain, and trismus, particularly in surgical cases such as third molar extractions and inflammatory neuropathies like Bell’s palsy.[10,19] These agents must be used with caution, especially in patients with uncontrolled diabetes, due to their potential to worsen glycemic control. For individuals with mucosal conditions or prosthetic irritation, topical agents such as lidocaine 2% gel, benzydamine hydrochloride mouthwash, and orabase with triamcinolone acetonide offer local pain relief without significant systemic exposure—making them suitable for patients with hepatic, renal, or cardiovascular comorbidities.[12] In pediatric patients with underlying conditions or increased vulnerability, teething pain can be managed with paracetamol as the first-line systemic agent due to its favorable safety profile. While lidocaine-based gels such as Bonjela® may offer topical relief, they should be used with strict caution to avoid systemic toxicity, especially in younger or low-weight children.[33] These adjunctive options complement the primary analgesic ladder and are particularly valuable in tailoring pain control to complex medical scenarios where systemic drug interactions or organ dysfunction limit standard analgesic use.

Discussion

This systematic review synthesizes the current body of evidence regarding the prescription of analgesics for dental pain, with a targeted focus on patients with medically compromised conditions. The analysis of 49 high-quality studies—including RCTs, systematic reviews, and clinical guidelines—emphasizes the necessity of individualized, evidence-based pharmacologic strategies that account for patients’ systemic medical vulnerabilities.

The findings confirm that while non-opioid analgesics, such as paracetamol and NSAIDs, remain the cornerstone for managing dental pain,[5,12,34] the specific medical conditions affecting each patient substantially influence both the safety and therapeutic efficacy of analgesic agents. For example, diclofenac potassium—owing to its enhanced solubility and rapid onset of action—has demonstrated superior efficacy in acute postoperative scenarios when compared to paracetamol and ibuprofen.[1,16,37] Moreover, the coadministration of paracetamol and ibuprofen has been consistently supported by meta-analyses, showing comparable effectiveness to opioids while mitigating associated adverse effects such as dependency, respiratory depression, and gastrointestinal complications.[36,39,40]

Based on the analgesic ladder constructed by the authors and the classification of analgesics provided in Table 1, it is essential for any practitioner prescribing analgesics to have a thorough understanding of the mechanisms of action of these drugs. Possessing such knowledge allows flexibility in adjusting treatment up or down the ladder—whether prescribing a single agent or combination therapy involving NSAIDs, corticosteroids, opioids, or non-opioids, and including or omitting adjunctive medications such as muscle relaxants, sedatives, or antidepressants. These strategies work collectively to alleviate various forms of dental and facial pain.[1,2]

Paracetamol acts centrally by reducing the sensitivity of bradykinin receptors in the hypothalamus, thereby dampening the amplification of pain signals originating from peripheral injury sites.[3] In contrast, NSAIDs exert their analgesic effect peripherally at the site of injury by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), which catalyze the conversion of arachidonic acid to prostaglandins—potent mediators of inflammation and pain.[4,5] Therefore, combining NSAIDs with paracetamol often results in enhanced analgesic efficacy due to their complementary mechanisms of action.[6]

Opioids provide analgesia by modulating pain transmission through binding to μ-opioid receptors in the spinal cord and brain. This action diminishes both the intensity and perception of pain signals, which is particularly beneficial in managing severe pain conditions such as trigeminal neuralgia and TMJ dislocation.[7] Sedatives like diazepam function as central nervous system depressants by binding to gamma-aminobutyric acid (GABA) receptors, enhancing inhibitory neurotransmission and reducing neuronal excitability.[8] Muscle relaxants such as baclofen target GABA-B receptors in the spinal cord and brain, inhibiting excitatory input to motor neurons and thereby decreasing muscle spasticity and tone. This mechanism is especially useful in TMJ disorders by relaxing the lateral pterygoid muscle, allowing for recapture of the displaced articular disc.[9,10]

To enhance the clinical application of these findings, Tables 1-3 were formulated to classify analgesics, align their use with specific medical risks, and guide their application through a structured, evidence-based analgesic ladder. Table 1 delineates drug categories and clinical indications; Table 2 presents recommendations tailored to distinct systemic disorders; and Table 3 outlines a tiered treatment protocol designed specifically for medically compromised dental patients. This ladder, developed in accordance with Cochrane and American Diabetes Association (ADA) guidelines, advocates for paracetamol as the first-line agent, combination therapy for moderate pain, and carefully monitored opioid use only in cases of severe pain.[3,5,7,37]

The analgesic ladder’s value lies in its safety, scalability, and adaptability to complex clinical presentations. For instance, NSAIDs are contraindicated in patients with hypertension or renal impairment; alternatives such as paracetamol or COX-2 inhibitors may be considered with careful monitoring.[30,34] In hepatic impairment, judicious use of paracetamol is acceptable, whereas opioids and high-dose NSAIDs should be avoided due to hepatotoxicity risks.[6] This individualized approach not only improves patient outcomes but also minimizes iatrogenic harm—an essential goal in managing complex dental cases.

From a pathophysiological standpoint, the cardiovascular risks associated with NSAIDs and selective COX-2 inhibitors are well established. Inhibition of COX-2 reduces prostacyclin (PGI2), a key vasodilator and antiplatelet mediator, while thromboxane A2 (TXA2) production via COX-1 remains unopposed. This imbalance promotes a pro-thrombotic state, increasing the risk of vasoconstriction, platelet aggregation, and thromboembolic events. Additionally, NSAIDs can impair renal perfusion and cause fluid retention, exacerbating hypertension and heart failure in predisposed individuals.[15,30,32,34]

The integration of adjunctive pharmacologic therapies further broadens the ladder’s clinical applicability. As outlined in Table 4, corticosteroids such as dexamethasone are highly effective in managing postoperative edema and trismus, as well as inflammatory conditions such as Bell’s palsy; however, they require careful administration in diabetic patients due to their hyperglycemic effects.[10,19] Topical agents—including lidocaine gel, benzydamine hydrochloride mouthwash, and orabase with triamcinolone—offer localized relief for mucosal lesions and denture-induced stomatitis, especially in patients where systemic analgesics are contraindicated.[12] For pediatric patients with teething-related discomfort, paracetamol is preferred for its safety, while lidocaine-based topical agents like Bonjela® must be used with caution to prevent systemic toxicity.[33]

This study was developed to support and streamline analgesic decision-making in both general and medically compromised dental populations. The analgesic ladder serves to eliminate inappropriate jumps between drug classes by encouraging a systematic approach based on pain intensity—ideally gauged using a validated pain scale.[38] For instance, initiating ibuprofen therapy in a patient with a history of peptic ulcer disease may provoke significant complications,[34,41] highlighting the necessity of thorough medical evaluation. Likewise, administering paracetamol for severe neuropathic pain, such as that seen in trigeminal neuralgia, is clinically inadequate; such cases may warrant opioid-based regimens.[20,21] In instances of trismus following multiple inferior alveolar nerve blocks, corticosteroid administration (e.g., 8 mg dexamethasone IM) is often required to mitigate inflammation and restore function.[10,19] Additionally, patients with TMJ disorders—often presenting with muscular tension, disc displacement, or hematoma—may benefit from the adjunctive use of muscle relaxants (e.g., baclofen) and anxiolytic agents (e.g., diazepam), which act synergistically by reducing neuromuscular stress.[23,24] The analgesic ladder, therefore, functions as a clinical beacon, guiding practitioners toward safe and appropriate therapeutic options while cautioning against potential pharmacologic hazards in medically vulnerable populations.[6,12,27,28,33]

Ultimately, this evidence-based ladder framework reflects a modern, personalized approach to dental pain management. It highlights that rational prescribing is less about choosing the most potent agent and more about selecting the safest and most effective therapy for each individual clinical context.[42,43,44,45,46,47,48,49]

Limitations and future research

This review is limited by the absence of a systematic methodology, largely due to the lack of sufficient high-quality RCTs addressing analgesic use in medically compromised dental patients. The heterogeneity of existing studies prevented formal bias assessment and meta-analysis. Despite these limitations, the review successfully proposes a structured analgesic ladder tailored to this complex patient population. It integrates multidisciplinary evidence to support clinical decision-making in the absence of uniform trial data.

Future research should focus on generating stronger clinical evidence, particularly through RCTs evaluating adjunctive analgesics such as muscle relaxants and neuropathic pain agents. Validating the proposed ladder in well-defined clinical settings will be crucial for improving dental pain management in medically compromised patients.

Conclusion

This review presents a practical, evidence-based protocol for analgesic use in dental patients, particularly those with systemic medical conditions. By combining pharmacologic classification, patient-specific risks, and a stepwise analgesic ladder, the model enables safer, individualized pain management. The inclusion of adjunctive agents—such as corticosteroids, muscle relaxants, sedatives, and topical therapies—enhances its versatility across diverse clinical scenarios. In summary, this framework promotes rational, patient-centered prescribing, guiding clinicians toward effective, ethical, and safe pharmacologic decisions in contemporary dental care.

Author contributions statement

G.G. and M.Z.N. conceptualized the review, conducted the literature search, contributed substantially to data analysis and interpretation, and were primarily responsible for drafting and critically revising the manuscript. E.O. contributed to the thematic organization of findings, provided clinical insight into pain management for medically compromised patients, and reviewed the manuscript for important intellectual content and clinical relevance. A.C. assisted in synthesizing pharmacological data, contributed to the interpretation of evidence across comorbid conditions, and helped revise the manuscript for clarity, consistency, and scientific rigor. All authors reviewed and approved the final version of the manuscript and agree to be accountable for its contents.

Conflicts of interest

There are no conflicts of interest.

Funding Statement

Nil.